Reasons for attending the AAD meeting | AAD 2024
John Barbieri, assistant professor at Harvard Medical School, is looking forward to the upcoming 2024 American Academy of Dermatology meeting, which runs from March 8-12 in San Diego. Barbieri is particularly showing interest in late-breaking abstracts and trial data and hoping to see cutting-edge information from pivotal clinical trials.
John Barbieri, M.D., MBA, is one of the more 17,000 dermatologists and others attending the American Academy of Dermatology’s annual meeting this weekend in San Diego.
Barbieri, an assistant professor at Harvard Medical School, says he is looking forward to the fresh troves of data and the connecting with colleagues.
“I love seeing the new trial data as it comes out, and the late breaking research sessions are a good place to find those,” Barbieri said in a recent interview. “I also find that AAD is a great time to connect with colleagues. I think that's one of the best parts of this meeting is being able to see all of our colleagues in dermatology to think about how we can collaborate, to think about how we can move the field forward together.”
Barbieri specializes in inflammatory skin disease such as acne, rosacea, psoriasis and atopic dermatitis. He is the director of the Advanced Acne Therapeutics Clinic at the Harvard-affiliated Brigham and Women’s Hospital in Boston and is the co-chair of the academy’s acne guidelines work group.
He is speaking at four sessions at the meeting, which started today and ends on Tuesday. The sessions he is speaking are titled Great Care for Common Conditions: Combining Evidence and Cost Effectiveness; JAAD [Journal of the American Academy of Dermatology] game changers; Controversies in Acne and Rosacea; and Translating Evidence Into Practice: Acne Guidelines and Beyond.
Phase 3 Trials of Oral Povorcitinib Show Positive Results in Hidradenitis Suppurativa
March 24th 2025A new drug application for povorcitinib is expected to be filed in late 2025 to early 2026 to treat adult patients with moderate to severe hidradenitis suppurativa, a chronic and painful inflammatory skin condition.
Read More
Opzelura May Reduce Need for Other Treatments in Atopic Dermatitis | AAD 2025
March 11th 2025Patients with atopic dermatitis who had not received biologics prior to treatment with Opzelura were able to avoid biologics during the 12 months after treatment with the topical nonsteroidal, according to study findings presented at the 2025 American Academy of Dermatology annual meeting.
Read More
Makeup and Skin Care Products Contain 'Forever Chemicals' | AAD 2025
March 10th 2025More than 200 products from 28 makeup, sunscreen, and shaving cream brands contained Teflon and other forever chemicals, according to a new study presented at the American Academy of Dermatology annual meeting.
Read More
Study Finds Opzelura Used As-Needed Improves Quality of Life | AAD 2025
March 10th 2025The reduction in itch was the greatest contributor to quality-of-life improvement for adolescents and adults with atopic dermatitis, according to a new study presented at the American Academy of Dermatology annual meeting.
Read More
